PubMed Health⌕ Search

Biomedical subjects

T Gundersen

Publications and source records attributed to T Gundersen.

At least 73 records · Page 4Linked to original sources
PubMed1983

Hearing acuity in a Norwegian standard population.

The hearing acuity in stratified age groups of men and women from 20 to 80 years were examined in a Norwegian county. The test subjects were randomly sampled to constitute a standard population. Of the 2343 people invited, 1474 attended. Of those who did not attend, 424 completed and returned a questionnaire. Mean pure-tone thresholds for both ears combined are presented for each sex separately and are given both as audiogram curves and numerically in tabular form. The most remarkable observation is a marked dip at 6 kHz in both sexes, even in the youngest examined age groups.

Adult↗
PubMed1983

Sustained haemodynamic effects of enalapril in left ventricular failure.

Enalapril, a novel angiotensin converting enzyme inhibitor, was given orally to 12 patients with chronic heart failure (NYHA functional class III and VI) and cardiomegaly. Heart rate, systemic arterial blood pressure, pulmonary arterial pressure, right and left ventricular filling pressures and cardiac index were monitored during dose efficacy titration. The optimal dose averaged 17 mg given once-daily. All patients were recatheterized three months later. After stabilization of cardiac filling pressures, all patients had left ventricular filling pressures in excess of 18 mmHg. Enalapril increased cardiac index acutely by 34% but at 12 weeks follow-up, cardiac index was not different from control levels. Left ventricular filling pressure was reduced acutely by 36% and by 41% at three months. Heart rate, systemic arterial and right atrial pressures and plasma concentrations of aldosterone were reduced during the observation period. Renin was markedly elevated. These changes were accompanied by marked and sustained clinical improvement and subjective well-being.

Aged↗
PubMed1982

Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Prepared for the Norwegian Multicentre Study Group.

Long-term treatment with timolol in patients ages 65--75 years who survived myocardial infarction was related to a significant reduction, compared with placebo, in overall mortality (p less than 0.05), total cardiac death (p less than 0.01), sudden death (p less than 0.05) and reinfarction (p less than 0.01). The analyses were based on 732 patients (384 taking placebo and 348 timolol) from a cohort of 1884 patients in the Norwegian multicenter timolol study. The dosage of timolol was 10 mg twice daily and the patients were followed for 12--33 months (mean 17 months). There were 83 deaths in the placebo group and 52 deaths in the timolol group, a reduction of 35.5%. There were 69 initial reinfarctions in the placebo group and 38 in the timolol group, a reduction of 39.2%. There was no difference in the reduction of mortality and reinfarction between patients 65--75 years of age and patients less than 65 years of age. The incidence of side effects, the number of withdrawals and the reasons for withdrawal were similar in older and younger patients. We conclude that age should not be a decision-making factor concerning timolol therapy in postinfarct patients.

Adrenergic beta-Antagonists↗
PubMed1982

Secondary prevention of myocardial infarction in the elderly.

A double-blind randomized Norwegian multi-centre study was carried out to compare the effect of timolol (10 mg twice daily) with that of placebo in patients, age between 20 and 75 years, surviving acute myocardial infarction. The patients were followed for 12 to 33 months (mean 17 months). There was a significant reduction in mortality and re-infarction in the patients treated with timolol. Results from the age group 65 to 75 years are analyzed in more detail in this study. Of the 1884 patients included in the main trial, 732 were between 65 and 75 years of age (348 taking timolol and 384 placebo). When analyzing all randomized patients in this elderly group, there were 83 deaths in the placebo group and 52 deaths in the timolol group (p = 0.03). During treatment or within 28 days of withdrawal, there were 62 deaths in the placebo group and 36 in the timolol group (p = 0.07). There were 69 first re-infarctions in the placebo group and 33 in the timolol group (p = 0.004). It is concluded that long-term treatment with timolol in patients aged 65 to 75 years surviving acute myocardial infarction reduces mortality and the rate of re-infarction.

Adult↗
PubMed1981

Yersinia pseudotuberculosis as the cause of septicaemia in a patient with liver cirrhosis. A case report.

Septicaemia caused by Yersinia pseudotuberculosis in a female patient, aged 22, is reported. She had suffered from a chronic active hepatitis for 14 years and had been treated with corticosteroids and azathioprine. The Y. pseudotuberculosis septicaemia responded well to treatment with doxycycline orally, but the patient died 2 weeks later because of excessive bleeding from varicose veins of the oesophagus.

Adult↗
PubMed1980

Doxycycline in the treatment of chlamydial urethritis: a therapeutic study.

The effect of doxycycline treatment was studied in 46 men with chlamydial non-gonococcal urethritis. Treatment with 200 mg doxycycline daily for 10 days rendered 22 of 22 patients free of urethritis. The treatment had no effect on the complications of urethritis like prostatitis and Reiter's syndrome. In the other group where 200 mg doxycycline was given on the first day and 100 mg on the subsequent days for 8 days, urethritis was resolved in 18 of 22 patients. C. trachomatis was not re-isolated from any of the patients after doxycycline treatment.

Adult↗
PubMed1979

Noise-induced hearing losses. Can they be explained by basilar membrane movement?

The development of noise-induced hearing losses must in some way be related to the basilar membrane movement. Our analysis of this relationship is based on Mössbauer effect measurements of the basilar membrane movement in human temporal bone preparations. At a single basilar membrane position in each of seven preparations, the displacement frequency response was measured for a given sound pressure level at the ear drum. The measurements covered the place range 2.2--6.2 kHz. Despite the inadequacy of the experimental data, there seems to be no doubt that low frequency components contribute substantially to the displacement and mechanical strain of the hair cells near the 4 kHz location, where the hair cells are known to be most vulnerable to noise damage. In fact, the analysis performed indicates that these cells will suffer the greatest mechanical strain, almost irrespective of the spectrum shape of the stimulus noise.

Basilar Membrane↗